Arena Pharmaceuticals Inc
Arena Pharmaceuticals' Pipeline Includes Bowel Disease Treatments
Cannabis Stocks Had a Mixed Performance Last Week
Cannabis ETFs traded on a largely negative note last week.
Key Cannabis Sector Updates: Analyst Ratings and Earnings
Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.
Semaglutide May Prove to Be an Effective Anti-Obesity Therapy
Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.
Saxenda May Continue to Lead in the Diabetes Segment in 2018
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.